Clik here to view.
Dipexium surpasses 50% treatment in Phase 3 trial
Dipexium Pharmaceuticals’ (NASDAQ:DPRX) OneStep-1 Phase 3 clinical trial has passed the 50% enrolment milestone. OneStep-1 and OneStep-2 are identical, pivotal Phase 3 clinical trials, with 180...
View ArticleClik here to view.
Dipexium hits 50% enrollment in second Phase 3 trial
Dipexium Pharmaceuticals’ (NASDAQ: DPRX) OneStep-2 pivotal Phase 3 clinical trial has reached the 50% enrollment milestone. OneStep-1 and OneStep-2 are identical, pivotal Phase 3 clinical trials, with...
View ArticleClik here to view.
Dipexium Phase 3 Locilex trials 62% enrolled
Dipexium Pharmaceuticals’ (NASDAQ:DPRX) OneStep Phase 3 placebo-controlled, pivotal clinical trials of Locilex in the treatment of patients with mild infections of diabetic foot ulcers are...
View ArticleClik here to view.
Dipexium Pharma gets Locilex patents in Australia and NZ
Dipexium Pharmaceuticals (NASDAQ:DPRX) said that Australia and New Zealand have issued new Locilex patents, with expiry dates in June 2033. The patents’ claims are directed to a novel formulation of...
View ArticleClik here to view.
Dipexium reaches 75% enrolment in Phase 3 trials
Dipexium Pharmaceuticals’ (NASDAQ:DPRX) OneStep-1 and OneStep-2 pivotal Phase 3 clinical trials have reached the 75% enrollment milestone in total, with each study having enrolled nearly the same...
View ArticleClik here to view.
In conversation with David Luci
David Luci As president, CEO and a co-founder of Dipexium Pharmaceuticals (NASDAQ:DPRX), David Luci, and executive chairman and co-founder, Robert DeLuccia, have spearheaded development of Locilex,...
View ArticleClik here to view.
Dipexium Pharma receives Locilex patent in Japan
Dipexium Pharmaceuticals (NASDAQ:DPRX) has received a patent in Japan, covering a novel formulation of Locilex, an antimicrobial peptide formulated as a topical cream. The issued patent has an expiry...
View ArticleClik here to view.
Dipexium completes enrollment in one Locilex Phase 3 trial
Dipexium Pharmaceuticals (NASDAQ:DPRX) has completed the patient enrollment objective in the OneStep-2 Phase 3 clinical trial of its Locilex topical antibiotic peptide. The company’s OneStep-1 Phase 3...
View ArticleClik here to view.
Dipexium Pharma presents new Locilex microbiology data
Dipexium Pharmaceuticals (NASDAQ:DPRX) and research collaborator, R. M. Alden Research Laboratory, presented data from two new Locilex microbiology studies at the American Society for Microbiology’s...
View ArticleClik here to view.
Dipexium, Tandem Diabetes make Feltl Best Ideas list
Dipexium Pharmaceuticals (NASDAQ:DPRX) and Tandem Diabetes (NASDAQ:TNDM) have made Feltl & Co.’s Best Ideas list for the second half this year. Analyst Ben Haynor writes that top-line data for...
View Article
